Abstract: Objective To investigate the effect of compound embryonic bovine liver extract in patients with hepatitis B related liver cirrhosis. Methods One hundred and twenty patients with hepatitis B induced liver cirrhosis were randomly divided into two groups,with 80 in treatment group receiving compound embryonic bovine liver extract tablets at the base of basic liver-protecting treatment and 40 in control group receiving the basic liver-protecting treatment only for 3 months. Liver function tests,liver stiffness measurement（LSM） by Fibrotouch,and portal vein diameters,spleen thickness and splenic vein width before and after treatment were compared in both groups. Results At the end of 3-month treatment,serum TBIL,ALT,and LSM values in patients in treatment group were（33.0±2.07） μmol/L,（36.40±5.86） U/L,（10.78±1.15） Kpa, respectively, significantly decreased as compared with those in the controls[（48.62±4.24） μmol/L,（52.60±7.3） U/L,（15.26±2.17） Kpa,respectively, P<0.05 for all];serum ALB levels in patients in treatment group increased significantly compared with that in controls[（35.0±1.58） g/L vs. （31±1.58） g/L,P<0.05];portal vein diameters,spleen thickness and splenic vein widths remarkably decreased compared with those in patients in the control group [（1.26±0.08） cm vs. （1.36±0.05） cm,（3.97±0.04） cm vs. （4.20±0.10） cm,（0.87±0.02） cm vs. （0.92±0.02） cm,P<0.05 for all]. Conclusions Compound embryonic bovine liver extract can significantly improve the liver function and inhibit liver fibrosis in patients with hepatitis B induced liver cirrhosis.

Key words: Liver cirrhosis, Compound embryonic bovine liver extract, Hepatitis B, Efficacy